Product logins

Find logins to all Clarivate products below.


Focal Segmental Glomerulosclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Focal Segmental Glomerulosclerosis (US)

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Although no drug therapies are approved for FSGS, physicians often prescribe RAAS inhibitors off-label to reduce proteinuria, and diuretics are commonly used to treat symptoms. Corticosteroid and immunosuppressive therapies are also considered for FSGS associated with clinical features of the nephrotic syndrome. However, owing to FSGS’s various etiologies and differences in presentation, management of the disease must be individualized. This report examines how key current therapies are being used to treat newly diagnosed and recently treated FSGS patients.

Questions answered

  • What patient shares do key therapies garner by line of therapy in newly diagnosed FSGS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed FSGS patients?
  • How are corticosteroids integrated into the treatment algorithm, and what is their source of business?
  • What percentage of FSGS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of FSGS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Key drugs: Alkylating agents, corticosteroids, diuretics, RAAS inhibitors.

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Rare Diseases and Orphan Drugs – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…